Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 7:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 686 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Rectal Cancer Stage II Clear all
Terminated Phase 1Phase 2 Interventional

A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients

NCT01300858
View directory record Official record
Conditions
Colorectal Cancer
Interventions
EGEN-001-301
Drug
Lead sponsor
EGEN, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 12, 2015 · Synced Sep 9, 2026, 7:58 AM EDT
Recruiting No phase listed Observational

Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer

NCT05081024
View directory record Official record
Conditions
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 9, 2026, 7:58 AM EDT
Terminated Not applicable Interventional

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

NCT00087191
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Gastrointestinal Carcinoid Tumor, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Primary Peritoneal Cavity Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Adult Soft Tissue Sarcoma, Recurrent Colon Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Small Intestine Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage 0 Non-small Cell Lung Cancer, Stage I Adult Soft Tissue Sarcoma, Stage I Colon Cancer, Stage I Gastric Cancer, Stage I Non-small Cell Lung Cancer, Stage I Ovarian Epithelial Cancer, Stage I Ovarian Germ Cell Tumor, Stage I Pancreatic Cancer, Stage I Rectal Cancer, Stage I Uterine Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage II Colon Cancer, Stage II Gastric Cancer, Stage II Non-small Cell Lung Cancer, Stage II Ovarian Epithelial Cancer, Stage II Ovarian Germ Cell Tumor, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage II Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Uterine Sarcoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Uterine Sarcoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
EF5, motexafin lutetium, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 9, 2026, 7:58 AM EDT
Completed Phase 2 Interventional Results available

Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery

NCT00290615
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, cetuximab, capecitabine, oxaliplatin
Biological · Drug
Lead sponsor
Herbert Hurwitz
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Sep 9, 2026, 7:58 AM EDT
Terminated Phase 2 Interventional

A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

NCT00040391
View directory record Official record
Conditions
Colorectal Neoplasms, Diarrhea
Interventions
Investigational drug, Irinotecan, 5-fluorouracil, Leucovorin
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
28
States / cities
Little Rock, Arkansas • Anaheim, California • Concord, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Sep 9, 2026, 7:58 AM EDT
Terminated Phase 2 Interventional Results available

AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer

NCT00397878
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
saracatinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 9, 2026, 7:58 AM EDT
Recruiting Phase 2 Interventional

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

NCT05672524
View directory record Official record
Conditions
Adenocarcinoma of the Rectum, Locally Advanced Rectal Adenocarcinoma, Rectal Adenocarcinoma, HER2 Positive Rectal Adenocarcinoma, Rectal Cancer
Interventions
Trastuzumab, Tucatinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 9, 2026, 7:58 AM EDT
Completed Phase 1 Interventional

Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer

NCT00134069
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
sorafenib tosylate, cetuximab, irinotecan hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Aurora, Colorado • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Sep 9, 2026, 7:58 AM EDT
Completed Phase 2 Interventional Results available

Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer

NCT00114231
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, oxaliplatin, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
67
States / cities
Scottsdale, Arizona • Concord, California • Duarte, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 9, 2026, 7:58 AM EDT
Completed No phase listed Observational

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

NCT00003329
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions
gene mapping
Genetic
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
0 Years to 120 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
32
States / cities
Rancho Mirage, California • Fort Collins, Colorado • Boca Raton, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 9, 2026, 7:58 AM EDT
Active, not recruiting Phase 2 Interventional

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

NCT04751370
View directory record Official record
Conditions
Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Radiation Therapy, Sigmoidoscopy, Total Mesorectal Excision
Procedure · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
213
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 145 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 9, 2026, 7:58 AM EDT
Completed Phase 2 Interventional

Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer

NCT00023751
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
178
States / cities
Anniston, Alabama • Mobile, Alabama • Phoenix, Arizona + 114 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 9, 2026, 7:58 AM EDT
Recruiting Phase 2 Interventional

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

NCT06780787
View directory record Official record
Conditions
Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Balstilimab, Biospecimen Collection, Botensilimab, Capecitabine, Computed Tomography, Digital Rectal Examination, Endoscopic Biopsy, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Radiation Therapy, Sigmoidoscopy
Biological · Procedure · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 9, 2026, 7:58 AM EDT
Completed Phase 1Phase 2 Interventional

Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction

NCT00004911
View directory record Official record
Conditions
Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Quality of Life, Small Intestine Cancer
Interventions
bowel obstruction management, quality-of-life assessment
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Sep 9, 2026, 7:58 AM EDT
Completed Phase 2 Interventional

Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec

NCT01116271
View directory record Official record
Conditions
Colorectal Cancer
Interventions
AZD6244, Irinotecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Los Angeles, California • Palm Springs, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2013 · Synced Sep 9, 2026, 7:58 AM EDT
Recruiting Phase 2 Interventional

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

NCT06792695
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 9, 2026, 7:58 AM EDT
Terminated Phase 2 Interventional Results available

Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma

NCT00625183
View directory record Official record
Conditions
Colorectal Cancer
Interventions
selenomethionine, capecitabine, oxaliplatin, laboratory biomarker analysis, pharmacological study, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy
Dietary Supplement · Drug · Other + 2 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 9, 2026, 7:58 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer

NCT00056030
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
cetuximab, fluorouracil, leucovorin calcium, oxaliplatin
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
162
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 103 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Sep 9, 2026, 7:58 AM EDT
Completed Phase 2 Interventional Results available

Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

NCT00022698
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Capecitabine, Irinotecan
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
17
States / cities
Birmingham, Alabama • Loma Linda, California • Norwich, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Sep 9, 2026, 7:58 AM EDT
Terminated Phase 2 Interventional Results available

Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

NCT03050814
View directory record Official record
Conditions
Colorectal Tumors, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Adenocarcinoma, Colorectal Cancer
Interventions
Avelumab, Ad-CEA vaccine, Bevacizumab, 5-Fluorouracil (FU), Leucovorin, Oxaliplatin, Capecitabine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2021 · Synced Sep 9, 2026, 7:58 AM EDT
Terminated Phase 1 Interventional

Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery

NCT01197664
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
paricalcitol, radiation therapy, laboratory biomarker analysis, fluorouracil
Drug · Radiation · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 9, 2026, 7:58 AM EDT
Recruiting Phase 2 Interventional

A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

NCT07058012
View directory record Official record
Conditions
Colo-rectal Cancer
Interventions
Cemiplimab, cemiplimab plus fianlimab, cemiplimab + REGN7075, ctDNA testing
Drug · Other
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
13
States / cities
Gainesville, Florida • Iowa City, Iowa • Kansas City, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 9, 2026, 7:58 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum

NCT00580073
View directory record Official record
Conditions
Rectal Cancer
Interventions
FOLFOX4, Cetuximab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 9, 2026, 7:58 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer

NCT00230399
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Celecoxib, Capecitabine, Irinotecan
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Sep 9, 2026, 7:58 AM EDT